Background: There is evidence that activation of coagulation by influencing tumour biology may have impact on clinical course of lung cancer.
Introduction
A growing body of evidence demonstrates that activation of coagulation is involved in fundamental processes during the evolution of cancer tissues, and is of major importance for invasive tumour growth and metastatic spread [1] . The activation of the clotting cascade can be due to activities expressed by the tumour cells themselves, or the stimulation of tumour-associated inflammatory cells, such as macrophages [2, 3] . Several activities in cultured human lung tumour cells [4] may contribute to activation of the tissue factor pathway, or of factors II or X directly. The substrates of coagulation (fibrinogen, clotting factors) are thought to reach the tumour tissue by diffusion after extravasation of plasma, facilitated by vascular permeability factor [1] . Also, platelet activation may be triggered by lung cancer cells via thrombin generation [5] . Well-documented clinical observations [6, 7] have shown an increased risk of thromboembolic complications early in the course of cancer.
Formation of a fibrin matrix appears to support tumour growth by promoting neoangiogenesis, and by shielding tumour cells against the attack of immunocompetent cells [8] . Thrombin may even be a growth * Dedicated to Professor KJaus Havemann on the occasion of his 65th anniversary.
factor for tumour cells [9] . In two controlled therapy trials, anticoagulation with warfarin as an adjuvant to chemotherapy was found to prolong survival of small cell lung cancer (SCLC) patients [10, 11] .
With sensitive molecular markers, in many lung cancer patients sustained activation of haemostasis can be demonstrated [12] [13] [14] . We could show [12] that the degree of activation of coagulation is related to initial tumour stage. The present study addresses the question, whether the extent of activation of coagulation, as assessed by pretherapeutic activation marker levels, has an impact on the response to subsequent standard antineoplastic treatment.
Patients and methods
In this prospective diagnostic study, 99 patients with newly diagnosed, histologically proven lung cancer, or relapse of lung cancer after previously documented complete remission, were evaluated. Patients with malignancies other than lung cancer, with pre-existing coagulation disturbances of other causes, on oral anticoagulant therapy, or who did not give their consent to participate, were not included. The study was approved by the local ethics committee.
The histologic type was small cell lung cancer (SCLC) in 41 patients, and non-small cell lung cancer (NSCLQ in 58 patients (29 squamous cell, 12 adeno, 17 large cell and mixed cell type). Complete tumour staging was carried out using standard procedures. In SCLC, the categories of tumour stage were adapted from criteria approved in a previous multicentre chemotherapy trial [15] , Extensive disease (ED) SCLC was defined as tumour with involvement of contralateral lymph nodes and/or metastases to other structures of the thorax and/or distant sites. In NSCLC, the non-resectable stages HIB and IV according to IUCC, were defined as ED. Altogether, the study included 46 ED patients (24 SCLC, six squamous cell, eight adeno, and eight large or mixed cell type). The other patients were assigned to the group of localised disease (LD).
All patients received primary standard antineoplastic treatment (typically four to six courses of chemotherapy, surgery or radiation) as appropriate for their histologic tumour type, stage, and their general condition. The outcome was documented by standard restaging procedures [15] ; for the purpose of this study, response (RSP) to treatment was defined as achievement of complete or partial remission, and nonresponse (NRSP) as no change, progressive disease or death before therapy could be completed.
None of the patients showed clinical signs or symptoms suggestive of recent thromboembolic disorders at the tune of inclusion into the study and blood sampling; diagnostic procedures such as Doppler sonography or phlebography to exclude occult thrombosis were not performed.
Blood samples were obtained before the start of antineoplastic treatment; the measured values of coagulation activation did not have any influence on decisions about modalities of tumour therapy. In order to determine in our laboratory reference ranges of the parameters in normal individuals, citrated blood samples were obtained from 32 healthy volunteers.
Methods
Blood samples were obtained using 10 ml syringes containing one part 3.8% sodium citrate to nine parts blood The citrated blood samples were immediately centrifuged at 1500 g for 15 min at room temperature. Aliquots were frozen at -40 °C until assay.
The activation markers thrombin-antithrombin complex (TAT) and prothrombin fragment Fi +2 (F 1+2 ) were determined by ELISA, using kits from Behringwerke (Marburg, Germany).
Statistical evaluation
The mean values and standard errors of means were calculated for groups according to the histologic types, the tumour stage at the time of diagnosis, the outcome in the entire study population and in the subgroup with ED, as well as for the healthy volunteer group. Differences between the groups were tested for significance by means of the alternate Welch's (-test for different variances, and significance was assumed at P values below 0.05. The distribution of patients with TAT levels above 6 ug/1 into the groups RSP and NRSP was analysed using contingency tables and Fisher's exact test.
Results
There was no difference in activation marker levels between patients with different histologic tumour types RSP NRSP Figure 1 . Distribution of the entire study patients according to their TAT levels (cut-off 6 ug/1) into the outcome categories RSP and NRSP.
(data not shown). The analysis of the entire study population showed that the values of RSP and NRSP were significantly different, as shown in Table 1 . In addition, the values of 32 healthy volunteers are displayed in order to show a reference range of the parameters in our laboratory; this group was not sex-and age-matched with the study population. The distribution of RSP and NRSP patients according to their TAT levels (cutoff 6 ug/1) is shown in Figure 1 ; the odds ratio was found to be 8.7 (95% confidence interval (CI) 2.7-27.6; P = 0.0014) for patients with TAT «S6 ug/1 to reach remission.
The TAT values were significantly higher in the patients with ED than in those with LD (Table 2) . Within the ED subgroup, as shown in Table 3 , the TAT values were lower in the RSP than in the NRSP patients; this difference was statistically significant despite the low number of RSP in the ED collective. The distribution of RSP and NRSP patients according to their TAT levels Table 3 . Activation marker levels (means ± SEM) within the subgroup with extensive disease (ED); patients achieving remission (RSP, n = 6) compared with the non-responders (NRSP, n -40). (cut-off 6 ug/1) is displayed in Figure 2 . The analysis shows that remission of their metastatic disease was achieved by 5 of 24 (20%) of patients with TAT ^ 6 ug/1, but only by 1 of 22 (4.5%) of patients with TAT > 6 ug/1. The odds ratio was 5.5 (95% CI 0.6-51.7); however, the difference was not significant in Fisher's exact test.
Discussion
This study confirmed previous results of this and other groups that activation of coagulation takes place in a large part of patient with lung cancer of any histologic type. In a previous paper [12] , we had been able to show that the plasma levels of markers demonstrating thrombin (TAT) and fibrin formations (D-dimers) are significantly higher in metastatic lung cancer. Since the difference was particularly pronounced for TAT, we decided to use the markers of thrombin generation TAT and Fi+2 for assessment of the prognostic impact of an activation of coagulation. In this study, 40% of patients showed elevated TAT levels; the TAT levels were much higher in patients with metastases. This might not only be due to their higher tumour mass, leading to a more pronounced activation of coagulation. It might also indicate that thrombin is mainly formed in the tumour tissue and 'leaks out' into the circulation, when the tumour is spreading. In this direction points also our finding that the difference between localised and metastatic disease is much more pronounced for TAT than for Fi +2 . This suggests that thrombin generation with cleavage of the large peptide prothrombin fragment Fi +2 might take place predominantly in a different compartment, i.e., tumour tissue, than the formation of complexes of thrombin with its inhibitor antithrombin in plasma. Already in our previous study [12] , we had found that elevated TAT values at the time of diagnosis were associated with worse outcome after subsequent treatment. However, this finding might have been due to the fact that among the patients with poor outcome there was a higher proportion with metastatic tumour disease and thus higher TAT levels. Therefore, we decided to analyse the subgroup of patients with prognostically unfavourable extensive disease separately. Also in this more homogenous patient group, there was a considerable difference of the TAT values between patients with effective therapy and the others. Remission was achieved by five of 24 ED patients with TAT ^ 6 ug/1, but only by 1 of 22 patients with TAT > 6 ug/1. Though this difference was not statistically significant in Fisher's exact test, probably due to the low number of remissions in the ED group, it appears to be remarkable (Figure 2 ). Since the tumour extension as could be assessed by standard diagnostic procedures and according to accepted staging criteria was comparable within the ED group, the higher levels in NRSP can not be explained merely by a more advanced tumour stage at the time of diagnosis and TAT determination. The data suggest that, in patients with lung cancer, the activation of coagulation is an independent prognostic factor. This interpretation is supported by experimental evidence pointing to several advantages for the tumour brought about by activated coagulation [1, 8, 9] .
It would be a major step forward in the so far often frustrating treatment of lung cancer, if a new, easy-tomeasure prognostic marker could support therapeutic decisions. In two controlled therapy trials, low grade anticoagulation with warfarin as an adjunct to regular chemotherapy has been found to prolong survival of small-cell lung cancer (SCLC) patients [10, 11] . This effect was statistically significant in both trials. However, it was not strong enough to prompt the adoption of this approach as part of the standard treatment of lung cancer. Two aspects might be considered in the interpretation of the two trials: 1) since unselected patients were treated, it appears likely that also patients without significantly increased coagulation received anticoagulation; 2) the warfarin doses were relatively low, possibly due to the fear of severe bleeding in those patients. The results of the present study raise the possibility that the determination of TAT could identify patients, who might have an advantage from anticoagulation as an adjunct to standard antineoplastic therapy. If this could be verified by further studies, TAT and other activation markers might also be helpful to monitor anticoagulation and find the appropriate individual therapeutic levels.
Further research should evaluate the potential value of diagnostic tests and therapeutic interventions directed at the activation of coagulation in the ongoing struggle to improve the outcome of lung cancer patients.
